CYP19A1 and breast carcinoma: In light of the aggregate of findings regarding CYP19A1 misexpression from gonadal promoters in breast cancer cases, Demura and Bulun postulated CYP19A1 pII/I.3 hypomethyaltion may contribute to the phenomenon of ‘promoter switching’ and inter-individual variability in lifetime estrogen exposure.